These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 26148596)
1. Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition. Richard SM; Martinez Marignac VL J Cancer Res Ther; 2015; 11(2):336-40. PubMed ID: 26148596 [TBL] [Abstract][Full Text] [Related]
2. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines. Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657 [TBL] [Abstract][Full Text] [Related]
3. Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells. Liu C; Liu Q; Yan A; Chang H; Ding Y; Tao J; Qiao C Cancer Med; 2020 Jun; 9(11):3875-3884. PubMed ID: 32248666 [TBL] [Abstract][Full Text] [Related]
4. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells. El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801 [TBL] [Abstract][Full Text] [Related]
5. Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells. Attoub S; Arafat K; Khalaf T; Sulaiman S; Iratni R Nutrients; 2018 May; 10(5):. PubMed ID: 29724012 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide. Flis S; Spłwiński J Anticancer Res; 2009 Jan; 29(1):435-41. PubMed ID: 19331183 [TBL] [Abstract][Full Text] [Related]
8. Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells. Hua H; Chen W; Shen L; Sheng Q; Teng L Acta Biochim Biophys Sin (Shanghai); 2013 Sep; 45(9):773-9. PubMed ID: 23786838 [TBL] [Abstract][Full Text] [Related]
9. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Xu JM; Azzariti A; Colucci G; Paradiso A Cancer Chemother Pharmacol; 2003 Dec; 52(6):442-8. PubMed ID: 13680161 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines. Rakitina TV; Vasilevskaya IA; O'Dwyer PJ Biochem Pharmacol; 2007 Jun; 73(11):1715-26. PubMed ID: 17343830 [TBL] [Abstract][Full Text] [Related]
11. Gercumin synergizes the action of 5-fluorouracil and oxaliplatin against chemoresistant human cancer colon cells. Genovese S; Epifano F; Preziuso F; Slater J; Nangia-Makker P; Majumdar APN; Fiorito S Biochem Biophys Res Commun; 2020 Jan; 522(1):95-99. PubMed ID: 31740005 [TBL] [Abstract][Full Text] [Related]
12. Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin. Lin YM; Chen CI; Hsiang YP; Hsu YC; Cheng KC; Chien PH; Pan HL; Lu CC; Chen YJ Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899208 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822 [TBL] [Abstract][Full Text] [Related]
14. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. Tanaka R; Ariyama H; Qin B; Shibata Y; Takii Y; Kusaba H; Baba E; Mitsugi K; Harada M; Nakano S Oncol Rep; 2005 Sep; 14(3):683-8. PubMed ID: 16077975 [TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Kornmann M; Fakler H; Butzer U; Beger HG; Link KH Anticancer Res; 2000; 20(5A):3259-64. PubMed ID: 11062751 [TBL] [Abstract][Full Text] [Related]
16. Down-regulation of p110β expression increases chemosensitivity of colon cancer cell lines to oxaliplatin. Liu W; Wang G; Cao X; Luo X; Li Z; Deng Y; Li X; Wang S; Liu M; Hu J; Wang J J Huazhong Univ Sci Technolog Med Sci; 2012 Apr; 32(2):280-286. PubMed ID: 22528234 [TBL] [Abstract][Full Text] [Related]
17. Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death. Ametller E; García-Recio S; Pastor-Arroyo EM; Callejo G; Carbó N; Gascón P; Almendro V Cancer Biol Ther; 2011 Jan; 11(1):4-13. PubMed ID: 20980803 [TBL] [Abstract][Full Text] [Related]
18. Low dose chemotherapeutic drugs without overt cytotoxic effects decrease the secretion of VEGF by cultured human tumor cells: a tentative relationship between drug type and tumor cell type response. Aktas SH; Akbulut H; Akgun N; Icli F Cancer Biomark; 2012-2013; 12(3):135-40. PubMed ID: 23481572 [TBL] [Abstract][Full Text] [Related]
19. The HDAC6 inhibitor ACY‑1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells. Lee DH; Won HR; Ryu HW; Han JM; Kwon SH Int J Oncol; 2018 Aug; 53(2):844-854. PubMed ID: 29749542 [TBL] [Abstract][Full Text] [Related]
20. Silencing of CD59 enhanced the sensitivity of HT29 cells to 5-Fluorouracil and Oxaliplatin. Yin H; Li C; Wang S; Guo Q; Ren X; Jiang G J Infect Chemother; 2015 Jan; 21(1):8-15. PubMed ID: 25444672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]